No Data
No Data
No Data
RIBOMIC: Financial Results Briefing for the Fiscal Year Ending March 31, 2024 (Q&A)
RIBOMIC: Financial results briefing materials for the fiscal year ending 2024/3
Ribomic Sees FY Loss Y1.41B
Ribomic Sees FY Loss Y1.41B
RIBOMIC: Summary of Financial Results for the Fiscal Year Ending March 31, 2024 [Japanese GAAP] (unconsolidated)
Brands that moved the day before part 2 PLANT, Sumiseki HD, Regil, etc.
<コード>Stock name closing price on the 24th ⇒ revised downward to the final major deficit due to Ahresty <5852> 647 -129 impairment recording compared to the previous day. Disgusted with potential dilution due to the issuance of Resonac <4004> 3390 -321CB. Profitable sales from fund shifts in the high price range of Hokkaido Electric Power <9509> 1155.5 -82.5. Orbic <4684> The rate of increase in sales for the fiscal year ending 20035 -16351-3 fell to the 1-digit range. Strike <6196> 4445 -365
Emerging Market Stock Digest: GENDA continues to rise drastically for 3 days, and Linkers stops high
<4586> Medlec 118 +2 repulsion. The operating profit and loss forecast for the fiscal year ending 24/12 has been revised upward from the previous deficit of 1,425 billion yen to a deficit of 1,183 billion yen (deficit of 933 million yen in the previous fiscal year results). Favorable pharmacokinetics and tolerability were shown in clinical phase 1 trials of the new drug candidate “Alto-101” in the central nervous system area, development milestones stipulated in a partnership agreement with the US drug discovery venture Alto have been achieved, and milestone revenue and paid clinical trial drug supply are expected
No Data